Mode
Text Size
Log in / Sign up

Prediction model for 30-day mortality in cancer patients with carbapenem-resistant organism infectionsResearchers develop model to predict death risk in cancer patients with resistant infections

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret this single-center mortality prediction model for CRO infections in cancer patients as requiring external validation.

A retrospective cohort study at Henan Cancer Hospital developed and validated a prediction model for 30-day mortality in 417 cancer patients with carbapenem-resistant organism (CRO) infections. The model incorporated 14 factors including sample source, radiotherapy history, blood culture positivity, antibiotic exposure, and various hematological biomarkers. No specific intervention or comparator was reported; the study focused on identifying factors associated with mortality risk.

The primary outcome was 30-day mortality prediction model performance. In the primary cohort, the model achieved an area under the ROC curve of 0.815 (95% CI: 0.767–0.857). In the validation cohort, performance was similar with an AUC of 0.801 (95% CI: 0.716–0.871). Model calibration was adequate in both cohorts, with Hosmer–Lemeshow test p-values of 0.479 (primary) and 0.786 (validation). The study did not report the actual mortality rate or event numbers.

Safety and tolerability data were not reported. The authors suggest the model could serve as an individualized risk prediction tool, but this is a single-center retrospective study that identifies associations rather than causation. The model requires external validation before clinical application, and its utility is based on decision curve and clinical impact curve analyses rather than implementation in practice.

Researchers at Henan Cancer Hospital studied 417 cancer patients who had infections caused by carbapenem-resistant organisms (CROs). These are serious infections that are hard to treat with common antibiotics. The goal was to create a tool to predict which patients were at highest risk of dying within 30 days of their infection.

The study looked back at patient records to find patterns. They identified 14 factors linked to higher risk, including where the infection sample came from, whether the patient had recent radiotherapy, and certain blood test results. The prediction model they built performed well in their initial group of patients and in a smaller validation group.

It's important to know this was a single-hospital study that looked at past data. The model shows associations but doesn't prove that changing any of the 14 factors would actually change a patient's risk. The researchers themselves say the model needs to be tested in other hospitals and patient groups before doctors could confidently use it in practice. For now, this is a promising research tool that could one day help doctors identify high-risk patients earlier.

What this means for you:
Early research creates a tool to identify cancer patients at highest risk from resistant infections; needs more testing before clinical use.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundThis study aimed to develop and validate a novel model for predicting mortality risk in cancer patients with carbapenem-resistant organism (CRO) infections.MethodsCancer patients with CRO infections in Henan Cancer Hospital between January 2022 and March 2024 were included in this retrospective study. LASSO regression was used to construct a novel model for predicting mortality in cancer patients with CRO infections. Receiver operating characteristic (ROC), decision curve analysis (DCA), and clinical impact curves (CIC) were used to assess the predictive ability and clinical utility of the prediction model.ResultsA total of 417 cancer patients with CRO infections were included in the study. Fourteen factors were selected, including sample source, radiotherapy, blood culture, exposure to antibiotics after susceptibility testing, lymphocyte-to-monocyte ratio (LMR), lymphocyte-to-monocyte ratio (LMR), total protein (TP), blood urea nitrogen (BUN), calcium (CA), C-reactive protein (CRP), triglyceride (TG), procalcitonin (PCT), prothrombin time (PT), and thrombin time (TT), which were found to be associated with 30-day mortality in cancer patients with CRO infections. The areas under the ROC curve for the prediction model were 0.815 (95% CI: 0.767–0.857) and 0.801 (95% CI: 0.716–0.871) for the primary cohort and validation cohort, respectively. The models demonstrated good predictive accuracy, with p-values 0.479 and 0.786 on the Hosmer–Lemeshow test. DCA and CIC analyses confirmed the clinical utility of the prediction model.ConclusionOur model could be used as an effective individualized risk prediction tool for clinicians. It would provide personalized risk assessments for cancer patients with CRO infections.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.